Description
The DEPCELL project is focused on validating the sorting of live, unlabeled mesenchymal stromal cells (MSC) using dielectrophoresis (DEP), linking this approach to telomere status and cellular replicative potential. The project aims to develop and validate a DEP platform developed by RTU under GMP-like conditions to support the preparation of advanced cell products within the Hospital Exemption framework. Simultaneously, an AI-assisted quality control workstation is being developed for real-time cell analysis. The validation primarily focuses on adipose tissue-derived MSC, with application prospects for patients with psoriasis, rheumatoid arthritis, and Crohn's disease.
The Achievable Results
The project's objective is to validate a laser-based processing method for producing antibacterial titanium surfaces. The project aims to demonstrate that laser-structured titanium can reliably reduce bacterial colonization under standardized laboratory conditions. By evaluating the process in terms of reproducibility, scalability, and suitability for industrial integration, the project will determine the potential of this technology for future applications in medical implants, particularly hip and knee prostheses.
The Anticipated Benefit
The project could promote the development of more precise and higher quality cell therapies for patients with psoriasis, rheumatoid arthritis, and Crohn's disease, especially in situations where existing treatments are not sufficiently effective. By developing a viable MSC selection and improved quality control, the safety, efficacy, and accessibility of future therapies in Latvia can be strengthened.